Fast-Moving Metabolon Raises $13.1M, Hints at IPO

Commercial success from Metabolon’s service arm is attracting investors and fueling development of its diagnostic R&D efforts. Metabolon is banking on its platform technology to indentify metabolomic biomarkers from which it plans to develop diagnostic tests for several diseases including ALS (http://www.metabolon.com/diagnostics/ALS.aspx).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail